These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 26267731)

  • 21. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
    Saurat JH; Stingl G; Dubertret L; Papp K; Langley RG; Ortonne JP; Unnebrink K; Kaul M; Camez A;
    Br J Dermatol; 2008 Mar; 158(3):558-66. PubMed ID: 18047523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.
    Faurschou A; Gyldenløve M; Rohde U; Thyssen JP; Zachariae C; Skov L; Knop FK; Vilsbøll T
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):555-9. PubMed ID: 25139195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial.
    Lajevardi V; Hallaji Z; Daklan S; Abedini R; Goodarzi A; Abdolreza M
    Int J Dermatol; 2015 Jan; 54(1):95-101. PubMed ID: 25209868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U; Kragballe K; Reich K; Griffiths CE; Gu Y; Wang Y; Rozzo SJ
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life.
    Ho SG; Yeung CK; Chan HH
    Clin Exp Dermatol; 2010 Oct; 35(7):717-22. PubMed ID: 19925489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
    van de Kerkhof PCM; Loewe R; Mrowietz U; Falques M; Pau-Charles I; Szepietowski JC
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):119-126. PubMed ID: 31465585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
    Gordon KB; Armstrong AW; Han C; Foley P; Song M; Wasfi Y; You Y; Shen YK; Reich K
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
    Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of adalimumab with methotrexate for psoriasis: A meta-analysis of randomized controlled studies.
    Yang X; Liu Y
    Medicine (Baltimore); 2024 Aug; 103(32):e37216. PubMed ID: 39121282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE; Sobell JM; Duffin KC; Bao Y; Guérin A; Yang H; Goldblum O; Okun MM; Mulani PM
    Br J Dermatol; 2012 Dec; 167(6):1374-81. PubMed ID: 22897348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Gordon KB; Kimball AB; Leonardi CL; Langley RG; Kimel M; Okun M
    J Dermatolog Treat; 2007; 18(6):341-50. PubMed ID: 18058494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.
    Augustin M; Blome C; Paul C; Puig L; Luger T; Lambert J; Chimenti S; Girolomoni G; Kragballe K; Naessens D; Bergmans P; Smirnov P; Barker J; Reich K
    J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):294-303. PubMed ID: 27515070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
    Gordon KB; Gottlieb AB; Langely RG; van de Kerkhof P; Belasco KT; Sundaram M; Okun M; Serra L
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):767-76. PubMed ID: 25284275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.
    Gordon KB; Betts KA; Sundaram M; Signorovitch JE; Li J; Xie M; Wu EQ; Okun MM
    J Am Acad Dermatol; 2017 Dec; 77(6):1030-1037. PubMed ID: 28993007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA; Blauvelt A; Kimball AB; Han C; Randazzo B; Wasfi Y; Shen YK; Li S; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
    Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
    J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.